Share
Digital therapeutics have been plodding on a steady path toward acceptance within healthcare, but the modality reached new heights during a year of unprecedented adoption for digital health technologies. More and more software-based treatments are picking up regulatory approvals – including three De Novo clearances in 2020 alone – while the ongoing COVID-19 pandemic has exposed more consumers, providers and other stakeholders to the technologies than ever before.
As the sector continues to find its footing, new players small and large will look to throw their hat into the ring. By doing so, they ll come to a crossroad that s very familiar to those with a background in the pharmaceuticals industry: whether to develop their new product in house or to in-license and release a promising candidate from academia or another company.
Share
Earlier this week DTx company Pear Therapeutics inked a deal with adherence tool etectRx to potentially develop a product that combines the former’s digital therapeutics with a digital pill offering. As part of the deal the two companies will meet quarterly to discuss potential collaborations with the pharma industry.
“Here we are talking about how can we bring this to pharma. we are going to quarterly, and we are going to talk about the market: Hey, what is pharma doing out there in clinical trials? Combing clinicaltrials.gov and approach them, and say could a combined solution like ours advance our clinical trials?” Valerie Sullivan, CEO of etectRx told
etectRx Announces Agreement to Advance Digital Sensors for Medication Adherence in Combination with Prescription Digital Therapeutics
News provided by
Share this article
Share this article
GAINESVILLE, Fla., Jan. 14, 2021 /PRNewswire/ Digital health company, etectRx, Inc., announced today that it has entered into an agreement with Pear Therapeutics, Inc. to develop up to two product candidates in the Central Nervous System (CNS) space combining Prescription Digital Therapeutics (PDTs) and adherence sensors. The collaboration is the first of its kind to explore the use of digital pill solutions with PDTs. This collaboration between etectRx and Pear Therapeutics comes at a critical time for the mental health field, an area that is in dire need of immediate solutions, said Valerie Sullivan, president and CEO of etectRx. Our goal for this collaboration is to bring concrete solutions to those who need it.
Pear Therapeutics Announces Publication of Economic Analysis Assessing the Cost-Effectiveness of reSET-O® in Treating Opioid Use Disorder (OUD)
By
Staff
4 months ago
reSET-O® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for patients with opioid use disorder (OUD).
New economic analysis showed reSET-O to be cost-effective compared to treatment-as-usual alone over 12 weeks, and to have economic dominance when contingency management (CM) was included as part of treatment as usual.
BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., today announced publication of a new economic analysis describing the cost-effectiveness of reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD). The analysis, “